Traditional Chinese medicine composition for treating hyperlipidemia and preparation method and application thereof
Preparation of sea buckthorn stock solution and a variety of traditional Chinese medicine compositions by low-temperature and low-pressure evaporation method, the side effects and high cost of existing drugs for treating hyperlipidemia are solved, the effect of reducing blood lipids and enhancing antioxidant capacity is achieved, and the major improvement of hyperlipidemia is significantly improved. The blood lipid levels and antioxidant capacity of the mice.
Patent Information
- Application Number
- CN202410729963.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing drugs for treating hyperlipidemia have side effects and are costly to be high, and it is difficult to effectively reduce blood lipids and enhance the body's antioxidant capacity.
The Chinese medicine composition is prepared by low-temperature and low-pressure evaporation method, and the volume ratio is as follows: sea buckthorn raw liquid and raw cassia, lotus leaves, yam, hawthorn, red cherry rice, orange peel, corn whisker, white marigold root, etc. The volume ratio is as sea buckthorn raw liquid: Chinese medicine The solution is 3-5:1, which is used to reduce blood lipids and enhance antioxidant enzyme activity.
In the experiment, the traditional Chinese medicine composition significantly reduced the blood lipid level of hyperlipidemia rats, improved the body's antioxidant ability, reduced the production of lipid peroxides, had small side effects, low cost, and enhanced the activity of superoxide dismutase, reducing the risk of reducing the The hazards caused by oxygen radicals.
Smart Images

Figure CN119015361A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating hyperlipidemia, and a preparation method and application thereof. Background Art
[0003] There is a close connection between abnormal blood lipid metabolism and obesity, and it can lead to a series of chronic diseases such as hypertension, coronary heart disease, diabetes, etc. At present, the drugs for treating hyperlipidemia are mainly traditional Chinese medicine and Western medicine, but long-term use of Western medicine will produce certain side effects. With the rapid development of modern medical culture, the market of herbal medicines is constantly expanding, and people are gradually inclined to use traditional Chinese medicine to treat hyperlipidemia.
[0004] The article "The lipid-lowering effect of composite seabuckthorn concentrate on hyperlipidemic rats" (Qin Nan, Wang Huimin, Yang Jinmei, etc., Food Industry Science and Technology, Vol. 44, No. 7, September 2022) reveals that the combination of seabuckthorn with hawthorn, raw cassia, lotus leaf, yam, red yeast rice, etc. may synergistically increase the lipid-lowering effect. The inventors found in the research that the formula can be further optimized. Summary of the invention
[0005] The technical problem to be solved by the present application is to overcome the defects and shortcomings of the above-mentioned related technologies and provide a new Chinese medicine composition formula based on the combination of seabuckthorn and lipid-lowering Chinese medicine. The Chinese medicine composition of the present invention has the effects of lowering blood lipids and anti-oxidation.
[0006] The present application provides a Chinese medicine composition for treating hyperlipidemia, comprising: seabuckthorn stock solution, and Chinese medicine liquid, wherein the Chinese medicine comprises raw cassia, lotus leaf, yam, hawthorn, red yeast rice, orange peel, corn silk, and Imperata root;
[0007] The volume ratio of seabuckthorn stock solution to traditional Chinese medicine solution is (3-5):1.
[0008] Furthermore, the traditional Chinese medicine is prepared from the following raw materials in the following weight proportions: 5-15 parts of raw cassia, 5-15 parts of lotus leaves, 5-15 parts of yam, 5-15 parts of hawthorn, 5-15 parts of red yeast rice, 5-15 parts of orange peel, 3-13 parts of corn silk, and 3-13 parts of Imperata root.
[0009] Furthermore, the traditional Chinese medicine is prepared from the following raw materials in the following weight proportions: 7-13 parts of raw cassia, 7-13 parts of lotus leaves, 7-13 parts of yam, 7-13 parts of hawthorn, 7-13 parts of red yeast rice, 7-13 parts of orange peel, 5-11 parts of corn silk, and 5-11 parts of Imperata root.
[0010] Furthermore, the traditional Chinese medicine is made of the following raw materials in the following weight proportions: 10 parts of raw cassia, 10 parts of lotus leaves, 10 parts of yam, 10 parts of hawthorn, 10 parts of red yeast rice, 10 parts of tangerine peel, 8 parts of corn silk, and 8 parts of Imperata root.
[0011] Furthermore, the Chinese medicine composition is a decoction.
[0012] The present application also provides a method for preparing the above-mentioned traditional Chinese medicine composition, comprising: mixing raw cassia, lotus leaf, yam, hawthorn, red yeast rice, tangerine peel, corn silk, and white imperata root and decocting them, filtering to obtain liquid medicine A and residues, decocting the residues to obtain liquid medicine B, combining liquid medicine A and liquid medicine B and concentrating them to obtain a traditional Chinese medicine liquid, and mixing the seabuckthorn stock solution with the traditional Chinese medicine liquid in a volume ratio of (3-5):1 to obtain the traditional Chinese medicine composition.
[0013] Furthermore, the above-mentioned concentration adopts a low-temperature and low-pressure evaporation method, such as a rotary evaporation method, which can achieve evaporation of solvent water at a relatively low temperature, and is more conducive to protecting the active ingredients in the drug solution.
[0014] The present application provides a medicine, comprising the above-mentioned traditional Chinese medicine composition and pharmaceutically acceptable excipients.
[0015] Furthermore, the Chinese medicine composition is used in the preparation of a medicine for treating hyperlipidemia.
[0016] Furthermore, the Chinese medicine composition plays a role in lowering blood lipids and blood sugar in drugs for treating hyperlipidemia.
[0017] Furthermore, the Chinese medicine composition plays a role in the treatment of hyperlipidemia by enhancing the activity of antioxidant enzymes in the body and reducing the production of lipid peroxides.
[0018] Beneficial technical effects of the present invention:
[0019] The traditional Chinese medicine composition provided by the invention has the effects of improving the blood lipid level of hyperlipidemic rats and enhancing the body's own antioxidant capacity.
[0020] Compared with the commonly used prescriptions or compounds for treating hyperlipidemia, the Chinese medicine composition uses medicines that are both medicine and food, has few side effects, and has low treatment costs. It also increases the activity of superoxide dismutase (SOD) by enhancing the activity of antioxidant enzymes in the body, thereby improving the body's own antioxidant capacity, reducing the production of lipid peroxides similar to malondialdehyde (MDA), and reducing the harm caused by oxygen free radicals. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 is a graph showing a change trend of the weight of rats in an embodiment of the present invention;
[0022] Figure 2 This is a rat liver picture of a preferred embodiment of the present invention;
[0023] Figure 3It is a pathological section diagram of mouse liver in an embodiment of the present invention; wherein, ① blank control group, ② high fat model group, ③ positive control group, ④ low-dose compound seabuckthorn oral liquid group, ⑤ medium-dose compound seabuckthorn oral liquid group, ⑥ high-dose compound seabuckthorn oral liquid group. DETAILED DESCRIPTION
[0024] The embodiments of the present invention are described in detail below. The following embodiments are implemented on the premise of the technical solution of the present invention, and detailed implementation methods and specific operation processes are given, but the protection scope of the present invention is not limited to the following embodiments.
[0025] Example 1
[0026] 1.1 Composition, source and preparation method of Chinese medicine composition
[0027] The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: 1200 mL of seabuckthorn stock solution, 7-13 g of raw cassia seed, 7-13 g of lotus leaf, 7-13 g of yam, 7-13 g of hawthorn, 7-13 g of red yeast rice, 7-13 g of orange peel, 5-11 g of corn silk and 5-11 g of Imperata root.
[0028] 1.2 Preparation method of Chinese medicine composition
[0029] Take 135g of the above Chinese medicine raw materials, add 1000mL of distilled water and boil for 20min, pour out the filtrate, add 600mL of water to the residue, boil at 85℃ for 20min; combine the two liquids and concentrate to 400mL of liquid. The obtained liquid is mixed with 1200mL of seabuckthorn stock solution to obtain a Chinese medicine composition liquid.
[0030] The obtained drug solution was cooled to room temperature and then stored in a refrigerator at 4°C for later use.
[0031] Example 2
[0032] The composition of the Chinese medicine composition of Example 2 is as follows:
[0033] 1200mL seabuckthorn stock solution, raw cassia 10g, lotus leaf 10g, yam 10g, hawthorn 10g, red yeast rice 10g, orange peel 10g, corn silk 8g, Imperata root 8g.
[0034] The Chinese medicine composition liquid of Example 2 was prepared by referring to the method described in 1.2 of Example 1.
[0035] Effect verification
[0036] 1. Efficacy study protocol
[0037] Modeling and grouping
[0038] After Wistar rats were adaptively fed with ordinary maintenance feed for 3 days, they were randomly divided into blank control group, high-fat model group, positive control group (1.80 mg / kg.bw), low (3.57 mL / kg.bw), medium (7.14 mL / kg.bw), and high (14.28 mL / kg.bw) dose groups of compound seabuckthorn oral liquid, with a total of 6 groups, 10 rats in each group.
[0039] During the modeling period, the blank control group was fed with basic maintenance feed, and the remaining groups were fed with high-fat feed. The TC level of the rats at the end of the experiment was used as the basis to judge whether the hyperlipidemia model was successfully established. After the modeling period, each drug-treated group should be gavaged according to the corresponding dose for 4 consecutive weeks, and the rats were weighed every three days, and the gavage amount of the test substance was adjusted in time according to the body weight.
[0040] After 28 days of oral administration of seabuckthorn compound liquid, the body weight, body length, serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), superoxide dismutase (SOD), and malondialdehyde (MDA) of the rats were measured, the liver tissue was pathologically examined, and the weight loss rate and LEE'S index were calculated.
[0041] At the end of the modeling period, the rats in the blank control group were still fed with basic maintenance feed, and the remaining groups were still provided with high-fat feed. During the experiment, the diet was not controlled, and free drinking water was guaranteed. The rats were kept in the animal room, and the temperature in the animal room was maintained at 23-26°C and the humidity was maintained at 30%-40%.
[0042] 2. Effect of compound seabuckthorn oral liquid on rat body weight and LEE'S index
[0043] The rats in each group grew normally during the experiment. As shown in Table 1, the body weight and LEE'S index of the rats in the high-fat model group were significantly higher than those in the blank control group (P < 0.05); the LEE'S index of the rats in the various dose groups of the compound seabuckthorn oral liquid and the positive control group was significantly lower than that in the high-fat model group, which was statistically significant (P < 0.05); after 28 days of intragastric administration, the body weight of the positive control group and the low, medium and high dose groups of the compound seabuckthorn oral liquid decreased by 12.94%, 5.03%, 6.86% and 7.02% respectively compared with the body weight of the high-fat model group; as shown in the attached Figure 1 It was concluded that after the formal administration began, as the number of days of gavage continued to increase, the weight of rats in the high-fat model group and each medication group showed an upward trend, and the weight trend of the medication group showed a slow increase, and the weight increase trend of the high-fat model group was more obvious. This shows that the compound seabuckthorn oral liquid can control the weight of rats fed a high-fat diet to a certain extent and reduce the obesity of rats.
[0044] Table 1 Effects of compound seabuckthorn oral liquid on body weight and LEE'S index of rats
[0045]
[0046] 2. Effect of compound seabuckthorn oral liquid on rat liver histopathology
[0047] 2.1 Effects on the gross morphology of rat liver
[0048] After killing the rats, the livers were separated as soon as possible and the morphology of the livers was observed with the naked eye. Figure 2 Observations: There were no obvious abnormalities in the livers of rats in the blank control group. The livers were dark red and uniform in color, regular in shape, with sharp edges and good toughness. The livers in the high-fat model group were significantly enlarged in volume, light in color, close to white, oily, obviously swollen and with rounded edges. The livers also had a certain degree of brittleness. Compared with the high-fat model group, the livers of the drug-treated groups were slightly darker in color, but the changes were not significant.
[0049] 2.2 Effects on rat liver coefficient
[0050] The liver coefficients of rats in each group were calculated, and the experimental results are shown in Table 2. The liver coefficient of the high-fat model group was significantly increased compared with that of the blank control group (P < 0.05); compared with the liver coefficient of the high-fat model group, the liver coefficients of the low-dose compound seabuckthorn oral liquid group and the positive control group were significantly decreased (P < 0.05), but the differences in the liver coefficients of rats in the medium-dose and high-dose compound seabuckthorn oral liquid groups were not significant. This shows that each drug administration group has a certain inhibitory effect on the increase of rat liver weight, and the compound seabuckthorn oral liquid has a certain lipid-lowering and weight-loss effect on rats.
[0051] Table 2 Effect of compound seabuckthorn oral liquid on rat liver coefficient
[0052] Group Liver coefficient Blank control group 0.030±0.002 High fat model group 0.037±0.003* Positive control group 0.033±0.004# Low dose group 0.034±0.002# Medium dose group 0.037±0.002 High dose group 0.035±0.002
[0053] 2.3 Effects on rat liver histopathology
[0054] HE staining was performed on rat liver histopathological sections. The results are shown in the attached figure. Figure 3 As shown. The liver tissue structure of the blank control group was normal, the liver lobules were clearly demarcated and arranged regularly, and the cell structure was clear and neatly arranged. The fatty degeneration of the liver tissue in the high-fat model group was severe, and a large number of hepatocytes were balloon-like in the liver parenchyma. The hepatocytes were extremely swollen and the cytoplasm was loose. The cells in the positive control group returned to normal, and a large number of fat vacuoles disappeared. Compared with the high-fat model group, the swelling degree of each dose group of the compound seabuckthorn oral liquid was reduced, and the fat vacuoles in the cytoplasm were significantly reduced. Therefore, it is shown that the compound seabuckthorn oral liquid can effectively reduce the blood lipid components in rats.
[0055] 3. Effects on blood lipid indexes in rats
[0056] After the experiment, the blood lipid indexes of rats in each group were tested, and the results are shown in Table 3. Compared with the blank control group, the TC, TG, and LDL-C levels in the serum of the hyperlipidemia model group were significantly increased (P < 0.05), and the HDL-C content was significantly reduced (P < 0.05), indicating that the hyperlipidemia rat model was successfully established. Compared with the blood lipid levels of the hyperlipidemia model group, the TC and TG levels in the serum of the positive control group and the high-dose group of the compound seabuckthorn oral liquid were significantly reduced (P < 0.05), and the TG content of the low- and medium-dose groups also decreased significantly (P < 0.05). At the same time, the LDL-C levels of rats in each drug-treated group were generally lower than those in the hyperlipidemia model group, and the HDL-C content increased, but there was no significant difference, indicating that the compound seabuckthorn oral liquid has the effect of lowering blood lipids in rats.
[0057] Table 3 Effects of compound seabuckthorn oral liquid on blood lipid indexes in hyperlipidemic rats (mmol / L, )
[0058]
[0059]
[0060] 4. Effects on Antioxidant Indexes in Rats
[0061] After the experiment, the antioxidant indexes of rats in each group were measured, and the results are shown in Table 4. Compared with the serum SOD activity level of rats in the blank control group, the serum SOD activity of rats in the high-fat model group was significantly decreased (P < 0.05), indicating that high-fat diet can lead to a decrease in SOD activity in rats. Compared with the SOD activity level of the high-fat model group, the SOD activity of each dose group of compound seabuckthorn and the positive control group was significantly increased (P < 0.05), indicating that the compound seabuckthorn oral liquid can improve the SOD activity of rats.
[0062] Compared with the MDA content of the blank control group, the MDA content of the high-fat model group increased significantly (P < 0.05), indicating that high-fat diet promotes lipid peroxidation in rats, thereby increasing the MDA content. Compared with the MDA content of the high-fat model group, the MDA content of the high-dose compound seabuckthorn oral liquid group decreased significantly (P < 0.05), and the MDA levels of each drug-administered group were lower than that of the high-fat model group, indicating that the compound seabuckthorn oral liquid can effectively alleviate lipid oxidation reactions in rats and reduce MDA content.
[0063] Table 4 Effects of compound seabuckthorn oral liquid on antioxidant indexes in hyperlipidemic rats
[0064] Group SOD content (U / mL) MDA content (nmol / mL) Blank control group 156.26±5.07 5.88±1.96 High-fat model group 130.70±4.09* 12.22±5.20* Positive control group 152.21±12.01# 5.10±2.91# Low dose group 153.03±10.82# 11.32±8.15 Medium dose group 147.75±13.79# 9.49±4.18 High dose group 154.91±13.42# 6.01±2.87#
[0065] The present application uses high-fat diet-induced hyperlipidemia rats as experimental subjects, and investigates whether the oral liquid has the effect of reducing blood lipids and anti-oxidation efficacy by gavage of different doses of composite seabuckthorn oral liquid. Hyperlipidemia can directly damage the antioxidant function on the arterial wall, accelerate systemic atherosclerosis and plaques, cause vascular endothelial cells to release a large number of free radicals, thereby causing a large amount of HDL-C to be oxidized. At the same time, hyperlipidemia can also cause the production and removal of free radicals in the body to lose balance, causing lipid peroxidation of biofilms, and producing MDA, SOD is a natural antioxidant enzyme that removes superoxide free radicals in the body, which can reduce the production of lipid peroxides. The above experimental results show that 3 different doses of composite seabuckthorn oral liquid can reduce TC, TG, LDL-C content in rat serum, increase HDL-C content, and increase SOD content, MDA is on a downward trend. The results showed that different doses of compound seabuckthorn oral liquid could improve the blood lipid levels of hyperlipidemic rats to varying degrees, and could increase the activity of SOD by enhancing the activity of antioxidant enzymes in the body, thereby improving the body's own antioxidant capacity, reducing the production of lipid peroxides similar to MDA, and reducing the harm caused by oxygen free radicals.
[0066] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. A Chinese medicine composition for treating hyperlipidemia, comprising: Sea buckthorn extract, and A Chinese medicine liquid, wherein the Chinese medicine liquid comprises raw cassia, lotus leaf, yam, hawthorn, red yeast rice, tangerine peel, corn silk, and Imperata root; The volume ratio of the seabuckthorn stock solution to the traditional Chinese medicine solution is (3-5):
1.
2. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine is prepared from the following raw materials in proportion by weight: 5-15 parts of raw cassia, 5-15 parts of lotus leaf, 5-15 parts of yam, 5-15 parts of hawthorn, 5-15 parts of red yeast rice, 5-15 parts of orange peel, 3-13 parts of corn silk and 3-13 parts of Imperata root.
3. The Chinese medicine composition according to claim 2, characterized in that: The traditional Chinese medicine is prepared from the following raw materials in proportion by weight: 7-13 parts of raw cassia, 7-13 parts of lotus leaves, 7-13 parts of yam, 7-13 parts of hawthorn, 7-13 parts of red yeast rice, 7-13 parts of orange peel, 5-11 parts of corn silk and 5-11 parts of Imperata root.
4. The Chinese medicine composition according to claim 3, characterized in that: The traditional Chinese medicine is prepared from the following raw materials in proportion by weight: 10 parts of raw cassia, 10 parts of lotus leaves, 10 parts of yam, 10 parts of hawthorn, 10 parts of red yeast rice, 10 parts of tangerine peel, 8 parts of corn silk and 8 parts of Imperata root.
5. The Chinese medicine composition according to any one of claims 1 to 4, characterized in that: The Chinese medicine composition is a decoction.
6. A method for preparing the Chinese medicine composition according to any one of claims 1 to 4, comprising: Raw cassia, lotus leaf, yam, hawthorn, red yeast rice, tangerine peel, corn silk and Imperata root are mixed and decocted, and filtered to obtain liquid medicine A and residues, the residues are decocted again to obtain liquid medicine B, liquid medicine A and liquid medicine B are combined and concentrated to obtain the traditional Chinese medicine liquid, and the sea buckthorn stock solution is mixed with the traditional Chinese medicine liquid in a volume ratio of (3-5):1 to obtain the traditional Chinese medicine composition.
7. A medicine comprising the Chinese medicine composition according to any one of claims 1 to 4 and pharmaceutically acceptable excipients.
8. Use of the Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating hyperlipidemia.
9. The use according to claim 8, characterized in that: The Chinese medicine composition is used in the medicine for treating hyperlipidemia to reduce blood lipids and blood sugar.
10. The use according to claim 8, characterized in that: The Chinese medicine composition is used in the medicine for treating hyperlipidemia to enhance the activity of antioxidant enzymes in the body and reduce the generation of lipid peroxides.
Citation Information
Patent Citations
Hyperglycemia-hyperlipidemia-hypertension relieving and yang strengthening tea
CN104095115A
Traditional Chinese medicine red yeast rice fermented by compound new substrate
CN105687979A
Cited By
Sea-buckthorn compound composition, sea-buckthorn compound active component, sea-buckthorn compound preparation and preparation method and application thereof
CN122272684A
